SEER - NASDAQ
Seer, Inc.
$1.86
-0.26%Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the secrets of the proteome. It develops Proteograph Product Suite, an integrated solution that comprises consumables, an automation instrumentation, and software that allows researchers to conduct proteomic studies in therapeutic and diagnostic research, and clinical trials. The company intends to sell its products for research purposes, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It has a collaboration agreement with Discovery Life Sciences, LLC. and the Salk Institute for Biological Studies. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.
At a Glance
Live SnapshotSeer, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Seer, Inc. Income Statement
SEER • NASDAQ
| Seer, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 |
|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||
16.6M | 13.9M | 15.2M | 14.7M | 6.4M | 656K | 58K | 0.0 | |
GROSS PROFIT | ||||||||
(8.1M) | (7.1M) | (13.7M) | (14.3M) | (6.8M) | (1.6M) | (701K) | (100K) | |
8.5M | 6.8M | 1.4M | 384K | -374K | -950K | -643K | -100K | |
OPERATING INCOME | ||||||||
(86.5M) | (106.9M) | (106.4M) | (98.4M) | (71.3M) | (32.7M) | (16.9M) | (6.8M) | |
(42.6M) | (56.6M) | (59M) | (52.6M) | (42.2M) | (15.4M) | (4.6M) | (3M) | |
(43.9M) | (50.6M) | (47.4M) | (45.8M) | (29.1M) | (17.3M) | (12.4M) | (3.8M) | |
-78M | -100.1M | -104.9M | -98M | -71.7M | -33.6M | -16.9M | -6.8M | |
PRE-TAX INCOME | ||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (22K) | (0.0) | (5K) | (0.0) | |
11.5M | 16.7M | 17.8M | 4.6M | 304K | 883K | 845K | 0.0 | |
(0.0) | -223K | (0.0) | (0.0) | (0.0) | (0.0) | -58K | (0.0) | |
4.6M | 13.6M | 18.7M | 5.1M | 527K | 874K | 845K | 451K | |
-73.4M | -86.5M | -86.3M | -93M | -71.2M | -32.8M | -16M | -6.3M | |
NET INCOME | ||||||||
(201K) | (98K) | (0.0) | (0.0) | (0.0) | (0.0) | (5K) | (0.0) | |
-73.6M | -86.6M | -86.3M | -93M | -71.2M | -32.8M | -16M | -6.3M |
SEC Filings
SEER - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 22, 2026 | May 21, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 04, 2026 | May 04, 2026 | 2026 | |
10-K/A 10-K/A 2025 FY (Amended) FY | April 30, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | April 27, 2026 | April 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 13, 2026 | April 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 30, 2026 | March 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 16, 2026 | March 13, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 02, 2026 | December 31, 2025 | 2025 |
Related Guides
Continue your SEER research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.